Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 78 mg/15 cm2 - anti-smoking agents - niquitin patches relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. they are indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin patches are indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin patches should be used in conjunction with a behavioural support programme

Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 114 mg/22 cm2 - anti-smoking agents - niquitin patches relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. they are indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin patches are indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin patches should be used in conjunction with a behavioural support programme.

Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 36 mg/ 7 cm2 - anti-smoking agents - niquitin patches relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. they are indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin patches are indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin patches should be used in conjunction with a behavioural support programme

Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 78 mg/15 cm2 - anti-smoking agents - niquitin clear relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. it is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin clear is indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin clear should be used in conjunction with a behavioural support programme.

Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 36 mg/ 7 cm2 - anti-smoking agents - niquitin clear relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. it is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin clear is indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin clear should be used in conjunction with a behavioural support programme.

Wielka Brytania - angielski - myHealthbox

omega pharma ltd - nicotine - transdermal patch. - 114 mg/22 cm2 - anti-smoking agents - niquitin clear relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. it is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin clear is indicated in pregnant and lactating women making a quit attempt. if possible, when stopping smoking, niquitin clear should be used in conjunction with a behavioural support programme.

Wielka Brytania - angielski - myHealthbox

mercury pharmaceuticals limited - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection - 3.75 mg - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones analogues - lutrate 1 month depot is indicated for palliative treatment of locally advanced or metastatic prostate cancer.

Wielka Brytania - angielski - myHealthbox

mercury pharmaceuticals limited - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection. - 22.5 mg - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones analogues - lutrate 3 month depot is indicated for palliative treatment of hormone dependent advanced prostate cancer.

Wielka Brytania - angielski - myHealthbox

chiesi gmbh - dipropionate anhydrous, formoterol fumarate dihydrate. - inhalation powder. - 200 micrograms/6 micrograms for metered dose - rugs for obstructive airway diseases; adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics. - fostair nexthaler is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair nexthaler is indicated in adults. note: there are no relevant clinical data on the use of fostair nexthaler for the treatment of acute asthma attacks.

Kanada - angielski - Health Canada

bausch health, canada inc. - betamethasone (betamethasone valerate); gentamicin (gentamicin sulfate) - cream - 0.1%; 0.1% - betamethasone (betamethasone valerate) 0.1%; gentamicin (gentamicin sulfate) 0.1% - antibiotics